Drugs / FXX489
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07144085 | Sep 2025 → Jul 2027 expected | metastatic malignant neoplasm | Yi Tian | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FXX489 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07144085 ↗ |
| Known as | NNS309 | “A new radiotracer, 68Ga-FXX489 (NNS309), has been developed for tracking fibroblast activation protein (FAP) and visualizing the tumor stroma.” NCT07144085 ↗ |
| Modality | Diagnostic / imaging agent | “A new radiotracer, 68Ga-FXX489 (NNS309), has been developed for tracking fibroblast activation protein (FAP) and visualizing the tumor stroma.” NCT07144085 ↗ |
| Route | Intravenous | “The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging.” NCT07144085 ↗ |
| Target | FAP | “tracking fibroblast activation protein (FAP)” NCT07144085 ↗ |